Download Files:
AD012
SKU
HY-143887-Get quote
Category Reference compound
Tags Angiotensin-converting Enzyme (ACE), Cardiovascular Disease, Metabolic Enzyme/Protease
Products Details
Product Description
– AD012 is a dual inhibitor of cACE/NEP. AD012 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD012 has the potential for providing the potent antihypertensive and cardioprotective benefits[1].
Web ID
– HY-143887
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C25H32N2O6
References
– [1]Arendse LB, et al. Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition. J Med Chem. 2022;65(4):3371-3387.
Molecular Weight
– 456.53
SMILES
– O=C([C@@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)CCCC)N[C@@H](CC2=CC=C(C=C2)O)C(O)=O
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Angiotensin-converting Enzyme (ACE)
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.